Publication

Article

CURE

Fall 2007
Volume6
Issue 5

Secondary Sarcomas

Some cancer therapies can increase the risk of secondary cancers such as sarcoma, especially for childhood cancer survivors.

Some treatments used to fight cancer carry an increased risk of developing other cancers later in life. A recent analysis of data from the Childhood Cancer Survivor Study found patients who were successfully treated for childhood cancer develop sarcoma at a rate nine times greater than the general population.

Factors associated with a higher risk of secondary sarcomas include a younger age at diagnosis of the first cancer (survivors diagnosed with their primary cancer between the ages of 1 and 3 had the highest risk); a family history of cancer; treatment with radiation; and chemotherapy with high doses of anthracyclines. The median age in the study for patients diagnosed with secondary sarcoma was 20, and about 70 percent were diagnosed before age 24.

Making a diagnosis of sarcoma can be difficult, and information about cancer risk factors can be of great use to doctors and patients. It’s important for childhood cancer survivors to make their doctors aware of their history to help them stay alert for secondary sarcoma.

Related Videos
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr Sattva S. Neelapu discusses data from the ZUMA-5 trial investigating the CAR T-cell therapy Yescarta in relapsed/refractory follicular lymphoma
Image of a woman with short brown hair, wearing glasses.
Image of a woman with brown shoulder-length hair, wearing a khaki colored blazer.
Image of a man wearing a black suit and tie.
Image of a man with rectangular glasses and a goatee.
Image of a woman with a brown hair tied into a bun.
Image of Dr. Jorge Cortes; a man with short dark hair wearing a suit.
Related Content